Foster City · Pre-Seed–Late Stage · 41 people tracked
Also known as IIF MANAGEMENT COMPANY, LLC
Find your way into Illumina Ventures
1,240 people in our graph share verified history with the Illumina Ventures team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Illumina Ventures positions itself as a leader in genomics and precision health investing. The firm concentrates on building the broader ecosystem around these fields and translating capital into innovation, with the stated goal of accelerating positive impact on human health.
Source: firm website, verified Sep 15, 2026.
Team · 41 people
from the firm's website & curated & public directories
Founder mafia
3 people who came through Illumina Ventures went on to found or lead other companies.
What they invest in
from 44 of 52 portfolio companiesBiotech ×41Healthtech ×17Deep Tech ×15AI & Machine Learning ×14Medical Devices ×12Digital Health ×10AgTech ×2Hardware ×2
HQs:United States×30United Kingdom×2Sweden×1
Who they back
founder profiles across 31 portfolio companiesFounding team size:solo founder×142 founders×73 founders×64+ founders×4
Where their founders studiedfrom 35 founders with education data
Massachusetts Institute of Technology ×3Case Western Reserve University ×2Fudan University ×2Harvard University ×2Sharif University of Technology ×2University of Cambridge ×2University of Oxford ×2University of Science and Technology of China ×2
What their founders studiedfrom 37 founders with field-of-study data
Life Sciences ×23Engineering ×6Mathematics & Statistics ×5Chemistry ×4Computer Science ×3Medicine ×3Physics ×3Business & Management ×2
Where their founders worked beforefrom 39 founders with career history
Harvard Medical School ×410x Genomics ×3Brigham and Women's Hospital ×3Harvard University ×3Massachusetts Institute of Technology ×3UC Berkeley ×3Broad Institute of MIT and Harvard ×2Brown University ×2
27 founders hold a PhD · 1 hold an MBA (of 37 with degree data)
Investments · 52 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 12024 · 12023 · 12022 · 42021 · 212 dated
Castle Biosciences develops genomic diagnostic tests that use a patient's molecular biology to inform disease management and treatment decisions.
BiotechDigital HealthHealthtechFriendswood, US
Derek Maetzold(Executive Officer, Director)inDerek J. Maetzold(President, CEO and Director)inFrank Stokes(Chief Financial Officer)inKristen Oelschlager(Chief Operating Officer)inToby Juvenal(Chief Commercial Officer)inHillary Caruso(Chief of Staff)in
Co-investorsBioBritMountain Group CapitalSofinnova HealthQuest Partners
Pattern develops rapid antibiotic susceptibility and infection diagnostics using single-cell microbiology, which reads the metabolic patterns of individual bacterial cells to deliver ID/AST results in hours without culture steps.
BiotechHealthtechMedical DevicesAustin, US
Nick Arab(Founder & CTO)Ross Johnson(Co-founder & Chief Engineer)inCarey-Ann Burnham(Chief Executive Officer)inTravis Davies(SVP, Operations)Kyle Fieleke(SVP, Corporate Development & Finance)David Bussian(SVP, Clinical, Regulatory & Assay Development)
Co-investorsAMR Action Fund
Pluton is developing a sun-powered, soil-surface biological nutrient system that uses photosynthetic microbial consortia to fix atmospheric nitrogen, improve phosphorus availability, and add carbon to soil for crop growers.
AgTechBiotechClimate TechSt. Louis, US
Barry Goldman(Co-founder)inElizabeth Gallegos(Chief Executive Officer)inJerry Steiner(Executive Chair)inCharlie Walch(Executive Officer, Director)inGlendon Schuster(Director)
Co-investorsFirst In VenturesRadicle GrowthBetter VenturesFall Line CapitalGrantham FoundationRA Capital+4 more
Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.
AI & Machine LearningBiotechDigital HealthBoston, US
Rehan Verjee(Co-Founder, Chief Executive Officer, Board Director)inSylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)inToni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)
Co-investors5AM VenturesOUP (Osage University Partners)Lilly Asia VenturesOsage University Partners
Predicta Biosciences operates a molecular insights platform for blood cancer care, using whole genome sequencing of intact circulating tumor cells from a single blood sample combined with single-cell immune profiling to characterize disease biology and immune response.
BiotechDigital HealthMedical DevicesCambridge, US
Irene Ghobrial(Co-founder)inKenneth Anderson(Co-founder)Gad Getz(Co-founder)Romanos Sklavenitis-Pistofidis(Co-founder)Keith Flaherty(Co-founder)Brian McKernan(CEO)in
Co-investorsThe Engine Ventures
RedShiftBio develops analytical technology that provides real-time measurement of biomolecular structure and concentration, aimed at supporting decisions in biopharmaceutical development and manufacturing.
BiotechDeep TechHardwareBoxborough, US
Thomas O'Lenic(Executive Officer, Director)Eugene Ma(Executive Officer)Charles Marshall(Executive Officer, Director)
BoardFrank Smith(Director)inWilliam Cadogan(Director)Bryson Hollimon(Director)
Co-investorsTechnology Venture Partners
Actym Therapeutics engineers bacteria as a delivery system for therapeutics targeting cancer and fibrotic disease.
BiotechHealthtechBerkeley, US
Christopher D Thanos(Executive Officer, Director, Promoter)Kanad Das(Director)Amit Kumar(Director, Promoter)James Huang(Director)
Adventris is a biotechnology company developing cancer immunotherapy treatments.
BiotechHealthtechBaltimore, US
Jen Herbach(Founder)inWilliam Collis(Founder)inMark Yarchoan(Founder)
Co-investorsY CombinatorRefactor Capital
Alamar Biosciences develops NULISA, an ultra-high-sensitivity, high-specificity technology for analyzing hundreds of protein biomarkers from small biofluid samples, building on the team's prior spatial genomics work (RNAscope).
BiotechDeep TechHealthtechFremont, US
Yuling Luo(Co-founder, CEO and Chair)inSteve Chen(Co-founder, COO and Director)inYiyuan Yin(Co-founder, VP of Technology)inTod White(President)inJustin McAnear(CFO)inXiao-Jun Ma(CTO)
Co-investorsQiming Venture PartnersSamsara BioCapital
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)ANNIE HAZLEHURST(Director)
BoardKEITH CRANDELL(Director)DAVID R. WALT(Director)in
Co-investorsARCH Venture PartnersOno Venture Investment, Inc.TCG CrossoverAlly Bridge GroupJanus Henderson InvestorsSection 32+3 more
Arima Genomics develops DNA-based cancer diagnostics that combine genomic sequence with 3D genome structural information (via Hi-C sequencing) to detect fusions, rearrangements, ecDNA, and other structural drivers of cancer.
BiotechHealthtechMedical Devices
Sid Selvaraj(Founder & Chief Operating Officer)inTom Willis(Chief Executive Officer)inAnthony Schmitt(Senior Vice President, Science)inErin Davis(Vice President, Marketing)in
Co-investorsBerkeley Catalyst
Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.
BiotechDigital Health
Zaneta Odrowaz(Founder)inTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)Zaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)
Co-investorsEcoR1 CapitalFrazier Life SciencesNextech InvestSanofi VenturesVida VenturesGoldman Sachs
Broken String Biosciences develops tools for genome-wide on- and off-target analysis in gene editing, enabling in-house detection and characterization of gene editing-induced DNA breaks.
AI & Machine LearningBiotechDeep Tech
Co-investorsFirst In VenturesHeran PartnersKorysMérieux Equity Partners
Bullseye Biosciences uses in-cell directed evolution to discover functional therapeutic molecules against challenging intracellular targets such as protein–protein interactions and transcriptional regulation.
BiotechDeep Tech
Corey Gray(Co-founder and CEO)inMichael McKeown(Co-founder and Head of Research)in
Co-investorsZAKA VC
BiotechPittsburgh, US
Michael Hoerres(Executive Officer, Director)
BoardJames Peters(Director)Steve Grenfell(Director)Paul Schmitt(Director)Noel Doheny(Director)
CubaseBio develops spatial biology tools that enable three-dimensional analysis of biological samples at scale, for drug discovery and biological research.
BiotechDeep TechStockholm, SE
Paulius Mielinis(Founder)inToon Verheyen(Founder)inXiaoyan Qian(Founder)in
Co-investorsLeksell Social VenturesNordic Science InvestmentsVoima Ventures
DeepSeq designs biologic drugs using AI trained on massive datasets of real protein interactions, predicting properties such as affinity, specificity, immunogenicity, pharmacokinetics, and manufacturability.
AI & Machine LearningBiotechDeep Tech
Bernhard Suter(Founder)in
Co-investorsZAKA VC
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Victor Velculescu(Executive Officer, Director, Promoter)inPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)in
BoardRishi Gupta(Director)in
Co-investorsAV8 VenturesForesite CapitalMenlo VenturesOpen Field CapitalOrbiMedOUP (Osage University Partners)+3 more
Encoded develops gene therapies for neurological disorders through an integrated platform approach.
Biotech
Stephanie Tagliatela(Founder)in
Co-investorsARCH Venture PartnersBioBritGV (Google Ventures)Menlo VenturesSoftBank Vision FundVenrock
Fluent Bio develops software for analyzing single-cell RNA sequencing data, producing count matrices and diagnostic outputs for researchers using Illumina sequencing libraries.
BiotechDeveloper Tools
Co-investorsCivilization Ventures Management, LlcCota CapitalSamsara BioCapital
Fuze Health operates a unified digital healthcare platform spanning digital pharmacy (FuzeRx), clinical services such as diagnostics, screening and genetics (Fuze Services), and data and technology tools (Fuze Technologies).
AI & Machine LearningDigital HealthHealthtechSaaS
Co-investorsHLM Venture PartnersK2 HealthVenturesOlive Tree CapitalSoftBank Vision FundTowerBrook
Genome Medical provides telehealth-enabled genetic services, including genetic counseling, genetic testing, and clinical trial matching, with a focus on individuals with rare conditions.
BiotechDigital HealthHealthtech
Mark Sylvester(Chief Financial Officer)inAndrew Warner(Vice President, Product)inMonica Zarb(Vice President, Business Development)inDurand Van Arnem(Vice President, Engineering)inAlan Rope(Medical Director)in
Co-investorsCanaan PartnersDreamers VCEcho Health VenturesGV (Google Ventures)Kaiser Permanente VenturesSamsung Catalyst Fund+5 more
Genome Medical provides telehealth-enabled genetic counseling, testing, and clinical trial access for patients with rare diseases.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsiSelect FundCanaan Partners
Hepta develops LiquidTransformer, an AI platform for analyzing cell-free DNA fragments in blood to detect chronic disease molecular signals.
AI & Machine LearningBiotechHealthtechSan Francisco, US
Hamed Amini(Founder)inSoheil Damangir(Founder)in
Co-investorsAlumni VenturesAME Cloud VenturesFelicis VenturesSeaX Ventures
Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors.
AI & Machine LearningBiotechDeep TechSan Diego, US
Tom Miller(Co-Founder & CEO)inFred Manby(Co-Founder & CTO)inThomas Miller(Founder)inNeil Josephson(Chief Medical Officer)inPete Olson(Chief Scientific Officer)inMichael Secora(Chief Financial Officer and Chief Corporate Development Officer)in
Co-investorsAbingworthAscenta CapitalCatalio Capital ManagementAlumni VenturesCatalio Capital Management, LPCoatue Management+4 more
Infinity Bio provides immune system analysis through its proprietary MIPSA antibody reactome profiling platform, which identifies the targets of individual immune responses against human viruses, human proteins (autoimmunity), and allergen proteins.
BiotechDeep TechHealthtechBaltimore, US
Benjamin Larman(Executive Officer, Director)inJoy M Nassif(Executive Officer, Director)in
BoardMatthew Hellauer(Director)Herman Scholtz(Director)inCaroline Popper(Director)in
Co-investorsTCP Venture CapitalPTX Capital
Integrated Biosciences is a biotech company developing small molecule therapeutics for age-related diseases, using optogenetics, chemistry, and AI to study aging biology.
AI & Machine LearningBiotechLongevityRedwood City, US
Felix Wong(Executive Officer, Director)inDaniel J. Anderson(Chief Scientific Officer)inThemasap Khan(Director)
BoardKeith Loebner(Director)
Co-investorsSutter Hill VenturesCivilization Ventures Management, Llc
Kallyope is a biotechnology company founded by neuroscientists that discovers and develops novel therapeutics targeting neural networks, with a lead candidate in pivotal studies for acute migraine treatment and metabolism programs approaching clinical studies.
BiotechHealthtechNew York City, US
Tom Maniatis(Director)Nancy Thornberry(Executive Officer, Director)inKenneth Clark(Executive Officer)
BoardTerry McGuire(Director)inJoshua Wolfe(Director)inTim Kutzkey(Director)in
Co-investorsDns CapitalLux CapitalThe Column GroupPolaris Partners
Kodikaz develops Zip-Code, a non-viral cell-specific delivery platform for gene therapy applications, particularly focused on oncology and cancer treatments.
AI & Machine LearningBiotechMedical DevicesAtlanta, US
Anthony Johnson(Co-Founder & CEO)inDr. Leon Bernal-Mizrachi(Co-Founder, CSO)in
Co-investorsEpidarex CapitalGRA Venture
Lightcast develops a single-cell functional analysis platform that uses droplet-based technology to profile cell function, biomolecule secretion, cell-cell interactions, and targeted cell killing at scale.
BiotechDeep TechHealthtech
Co-investors+ND CapitalLongwall Venture Partners LLPM VenturesOMX VenturesARCH Venture Partners
Lightcast provides a next-generation single-cell functional analysis platform called Envisia that enables massively parallel profiling of cell-cell interactions and biomolecule secretion at scale.
BiotechDeep TechMedical DevicesCambridge, GB
Co-investorsARCH Venture PartnersPerscitus LLP
San Diego, US
Bob Kain(Executive Officer, Director)inDawn Barry(Executive Officer)inJoseph C. Beery(Executive Officer, Director)
Co-investorsARCH Venture PartnersBain Capital VenturesF-Prime CapitalOsage University Partners
NanoCellect develops microfluidic-based cell sorters that operate at low pressure to sort cells with high viability and reduced shear stress, aimed at scientists and researchers.
BiotechHardwareMedical Devices
Chris Neary(CEO)in
Co-investorsVertical Venture PartnersWarburg PincusFusionX Ventures
NuCicer develops improved crop varieties through selective breeding, starting with high-protein chickpeas designed for better nutrition.
AgTechAI & Machine LearningFoodTechDavis, US
Kathryn Cook(Executive Officer, Director)inDouglas Cook(Executive Officer, Director)
BoardPaimun Amini(Director)inJerry Steiner(Director)inCarsten Boers(Director)in
Co-investorsBetter Ventures Central LlcBlue Horizon CorporationLever VCRhapsody Venture PartnersStray Dog Capital
.png)
Oncko develops machine learning and experimental platforms to discover optimized multi-drug cancer treatment combinations by screening against resistance mechanisms.
AI & Machine LearningBiotechDeep Tech
Atray Dixit(Co-founder, CEO)inBill Grossman(Co-founder, Strategic Advisor)in
Co-investorsAdverb VenturesTenmile
Protillion Biosciences develops platform technology for antibody engineering and drug discovery.
AI & Machine LearningBiotechDeep TechCarlsbad, US
Curtis Layton(CEO/Co-Founder)inDavid Walt(Co-Founder)inWill Greenleaf(Co-Founder)inRobert Hollingsworth(Chief Scientific Officer)in
.png)
BoardSean Kendall(Director)inMalek Faham(Director)in
.png)
Co-investorsARCH Venture Partners
Santa Clara, US
Jekwan Ryu(Executive Officer, Director)Ronald M. Cook(Director)Eric Williams(Executive Officer)Tae Hoon Nahm(Director)
BoardTom Willis(Director, Executive Officer)
BiotechGreenville, US
Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)
Co-investorsHatteras Venture PartnersM VenturesMC Healthcare VenturesPappas CapitalSV Health InvestorsDementia Discovery Fund+1 more
Serinus Biosciences uses AI and systems biology to design drug combinations that overcome cancer cells' resistance to existing treatments, targeting safer and more effective therapeutic options.
BiotechHealthtechNew York City, US
Adam Yaari(Founder/CEO)inMaxwell Sherman(Founder/CTO)in
Co-investorsMetaplanetY Combinator
HealthtechCambridge, US
Rahul Dhanda(Executive Officer, Director)inJames Collins(Director)David Walt(Director)in
BoardIssi Rozen(Director)in
Co-investorsCatalio Capital Management, LPCatalio Capital ManagementGood VenturesGV (Google Ventures)Northpond VenturesNovalis LifeSciences
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Co-investorsVida VenturesLeaps by BayerFoothill VenturesMedical Excellence CapitalVivo CapitalARCH Venture Partners+1 more
Syntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation.
BiotechDeep TechMedical DevicesChicago, US
Ryan Clarke(Co-Founder, Chief Scientific Officer)inNiko Balanis, PhD(Co-Founder, Chief Technology Officer)inBrad Merrill, PhD(Co-Founder, Head of Innovation)Matt MacDougall, MD, PhD(Scientific Cofounder, Immunology Physician, Stanford University)inJohn Craighead, PhD(Chief Executive Officer)
Co-investorsAstellas Venture Management LLCDCVC (Data Collective)DCVC BioDraper AssociatesPortal Innovations
Tagomics develops multimodal technologies for precision medicine and next-generation diagnostics.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, GB
Dr Jack Kennefick(Co-founder, Director & Chief Executive Officer)Dr Robert Neely(Co-founder, Director & Chief Scientific Officer)
Co-investorsIQ CapitalCalculusCalculus Capital Ltd.MEIF Proof-of-Concept & Early Stage FundMercia VenturesOMX Ventures+1 more
.jpeg){kind=logo}
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
DNA ScriptDnascriptEncodedgenomicsNanoCellect BiomedicalPattern BiosciencePattern Bioscience, Inc.PredictaStilla Technologies
Exits · 1
1 IPOsCastle BiosciencesNASDAQ: CSTL
Portfolio news
latest coverage across their companiesAttovia Therapeutics · ca.investing.com · Aug 7, 2026
SonoThera · statnews.com · Jul 17, 2026
Pattern · investing.com · Jul 14, 2026
Delfi Diagnostics · geekwire.com · Jul 13, 2026
Iambic · geekwire.com · Jul 13, 2026
Lightcast · kb.lightcast.io · Jul 2, 2026
Syntax · bizjournals.com · Jun 23, 2026
Protillion Biosciences · genengnews.com · Jun 18, 2026
Frequently asked questions
- How many investments has Illumina Ventures made?
- Illumina Ventures has 52 tracked investments, 1 of which have exited, including 4 dated in the last 24 months.
- What stage does Illumina Ventures invest at?
- Illumina Ventures invests at the Pre-Seed, Seed, Series A, Late Stage stages.
- What sectors does Illumina Ventures focus on?
- Illumina Ventures focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Illumina Ventures located?
- Illumina Ventures is headquartered in Foster City, US.
- Does Illumina Ventures lead rounds?
- Illumina Ventures typically participates in rounds rather than leading them.
- Who does Illumina Ventures co-invest with?
- Illumina Ventures most often shares deals with ARCH Venture Partners, Samsara BioCapital, GV (Google Ventures), among 87 tracked co-investors.
- What size deals does Illumina Ventures back?
- Across 6 deals with disclosed amounts, Illumina Ventures has joined rounds of $6.7M – $215M (median $53.5M).
Co-investors · 11
Catalio is a software platform that uses AI to automatically extract and document business logic from legacy and modern systems, creating living specifications that stay current as software evolves.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Kurma Partners is a European healthcare-focused investment firm that co-founds and finances biotech and healthcare companies, working closely with research centers to translate scientific discoveries into high-tech companies.
Qiming Venture Partners is a Shanghai-based venture capital firm that invests in growth-stage technology, communications, media, and healthcare companies operating in China, with support from its U.S. partner Ignition Partners. The firm's investment approach combines local market knowledge with global resources and executive relationships.
+ND Capital is an investment firm founded in 2002 focused on nanotechnology and deep science ventures, backing companies emerging from breakthroughs at the nanoscale.
Casdin Capital is an investment firm focused on the life sciences, investing across healthcare, biotechnology, synthetic biology, and related technology.
Transformation Capital is an investment firm focused exclusively on the healthcare industry, backing companies transforming healthcare delivery and services.
Paladin Capital Group invests in early stage and growth companies developing cyber, AI and deep technologies that address security and resilience needs for commercial and government customers.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Genoa Ventures is a venture capital firm that works with strategic partners providing market insights, validated deal flow, and domain expertise to support its portfolio companies.
Firms observed investing alongside Illumina Ventures, from public investor directories. Shared companies are the overlap with Illumina Ventures's recorded portfolio.
Similar investors
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Lumira Ventures is a North American life sciences venture capital firm that partners with mission-driven entrepreneurs to build companies developing and commercializing healthcare products for patients.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.